Moleculin Biotech Secures Australian Patent for Annamycin Formulation

Moleculin Biotech, Inc. announced the grant of an Australian patent covering the preparation of preliposomal Annamycin lyophilizate. This patent strengthens the company's intellectual property protection for a crucial aspect of Annamycin's formulation technology. The Australian patent is part of Moleculin's broader global intellectual property strategy, which includes granted or allowed patents in numerous countries and applications pending in others, aiming to protect various complementary technologies associated with Annamycin.